Novo Nordisk A/S (NYSE:NVO) is Nichols & Pratt Advisers LLP MA’s 10th Largest Position

Nichols & Pratt Advisers LLP MA lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 502,600 shares of the company’s stock after selling 6,460 shares during the quarter. Novo Nordisk A/S comprises 3.7% of Nichols & Pratt Advisers LLP MA’s portfolio, making the stock its 10th largest position. Nichols & Pratt Advisers LLP MA’s holdings in Novo Nordisk A/S were worth $51,994,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of NVO. Pacific Center for Financial Services raised its position in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Bell Investment Advisors Inc boosted its position in shares of Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the period. CNB Bank purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $26,000. Tyler Stone Wealth Management raised its stake in Novo Nordisk A/S by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after acquiring an additional 146 shares during the last quarter. Finally, West Paces Advisors Inc. boosted its position in Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after purchasing an additional 150 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NVO has been the topic of a number of analyst reports. UBS Group started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded down $0.03 during mid-day trading on Friday, reaching $128.63. The stock had a trading volume of 1,548,309 shares, compared to its average volume of 4,768,386. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The business’s 50 day moving average price is $127.61 and its 200 day moving average price is $113.70. The company has a market cap of $577.23 billion, a P/E ratio of 44.63, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.